In an effort to speed more generic drug approvals, the FDA said it is changing how it assigns priority review status to abbreviated new drug applications.
The FDA released another set of changes this week, this time changing how abbreviated new drug applications (ANDAs) are prioritized for review so that the agency’s resources are allocated to generic drugs that would have the biggest impact on public health.
Before, “roughly half of all ANDA submissions were designated as priority submissions, including many products that could not be marketed for several years as a result of blocking patents or exclusivities,” according to Sally Choe, PhD, director of the Office of Generic Drugs in the FDA’s Center for Drug Evaluation and Research.
Under the previous version of the Manual of Policies and Procedures (MAPP) 5240.3, Prioritization of the Review of Original ANDAs, Amendments, and Supplements, the FDA prioritized submissions from first filers and from applicants with paragraph IV certifications, even though the drugs would not be able to come to market for years due to a patent, 30-month stay, or exclusivity blocking final approval. A paragraph IV certification is a generic applicant’s assertion that the brand-name product’s patents listed in the Orange Book are invalid, unenforceable, or will not be infringed by the proposed generic product.
This did not improve generic drug access, the FDA said; wider access could have the effect of “potentially lowering costs by expediting the availability of safe, high-quality, effective generic medicines in areas of the market with limited competition,” said Choe.
Under the change, an original ANDA must meet certain criteria in order to have a priority review. Those include:
Among other things, prioritization factors include:
The change applies to both regular generic drugs as well as complex generics, which generally mean drugs with complex active ingredients, complex formulations, complex routes of delivery, or complex dosage forms.
Separately, the House Energy and Commerce Committee made a bipartisan request earlier this month to FDA Commissioner Stephen Hahn, MD, asking for additional information about the approval process for complex generic drugs. According to the letter, the representatives want information about whether the agency’s “initiatives and commitments are sufficient to address the particular challenge of approving complex generic drugs” and to find out if “additional authority is needed to improve the approval process for complex generic drugs to increase access and reduce costs.”
Among other things, the committee asked for a list of list of all complex generic drugs approved by FDA since October 1, 2016, including the date of the first submission, the dates of other milestones and the date of approval, and the number of pre-ANDA meeting requests that FDA has received each year since the program was launched, the number of pre-ANDA meetings that FDA has held each year, and. the number of ANDAs that have been submitted for products discussed during these meetings.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability
April 30th 2024During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.